Abstract

    Open Access Mini Review Article ID: AHR-7-128

    Lipid nanoparticulate drug delivery system for the treatment of hepatic fibrosis

    Swarupananda Mukherjee*, Ayon Dutta and Dipanjana Ash

    Background: Irreversible hepatic fibrosis, an excessive production and accumulation of extra cellular matrix by hepatic stellate cells in the liver, becomes a remarkable economic burden in global health care system.Low therapeutic efficacy and undesirable systemic effect of conventional therapies limit their clinical applications to targethepatic stellate cells.

    Method: Surface engineered lipid nano-particle becomes a potential candidate to deliver anti-fibrotic nutrients or Small interfering RNA (siRNA) of fibrogenic genes for treating hepatic disorders. 

    Conclusion: This mini review focuses on different strategies of surface engineered organic lipid nanoparticles for the treatment of hepatic fibrosis by targeting specific and un-specific Hepatic Stellate Cells (HSCs).

    Keywords:

    Published on: Jan 28, 2021 Pages: 1-3

    Full Text PDF Full Text HTML DOI: 10.17352/ahr.000028
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat

    Indexing/Archiving

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on AHR

    Google Reviews 11